In 2025, the companies within AddLife continued to develop positively, with improved profitability and stronger cash flows.
The demand for healthcare is constantly increasing, while new technologies in diagnostics and research enable earlier and more patient-specific diagnostics. At the same time, there is an ongoing staff shortage and growing patient waiting lists. In this environment, solutions that increase productivity, free up time for healthcare professionals, and improve clinical outcomes are becoming increasingly important. During the year, AddLife’s companies have met this need with advanced products, digital solutions, and strong, trusted local service organisations that ensure that new technologies and methods work in customers’ operations.

Improving margins remained the highest priority during the year. Through efficiency improvements, more active pricing and a gradual shift in the product portfolios towards more advanced and profitable offerings, the companies have further strengthened their positions and margins. Both business areas clearly improved their EBITA margins for the full year, with Labtech at 12.5 percent (11.7) and Medtech at 12.4* percent (11.5).

^{* Adjusted for divestment of operations}

Our business areas

Medtech is the largest business area and accounts for 62 percent of sales, while Labtech accounts for 38 percent.